Bionoid Pharma, Inc.
BINP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $38 | $36 | $102 |
| % Growth | -100% | 4.1% | -64.7% | – |
| Cost of Goods Sold | $277 | $29 | $19 | $56 |
| Gross Profit | -$277 | $8 | $17 | $46 |
| % Margin | – | 22.4% | 48.1% | 45.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $16 | $15 | $126 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $16 | $15 | $126 |
| Operating Income | -$277 | $13 | $2 | -$80 |
| % Margin | – | 36% | 5.2% | -78.2% |
| Other Income/Exp. Net | -$2 | -$2 | -$0 | -$55 |
| Pre-Tax Income | -$278 | $12 | $1 | -$135 |
| Tax Expense | $0 | -$8 | $0 | $0 |
| Net Income | -$317 | $12 | $1 | -$135 |
| % Margin | – | 31.3% | 4.1% | -132.2% |
| EPS | -0.005 | -0 | 0 | -0.003 |
| % Growth | -4,900% | – | 100% | – |
| EPS Diluted | -0.005 | -0 | 0 | -0.003 |
| Weighted Avg Shares Out | 53,995 | 53,995 | 53,995 | 42,665 |
| Weighted Avg Shares Out Dil | 53,995 | 53,995 | 53,995 | 42,665 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $0 | $0 |
| Depreciation & Amortization | $277 | $3 | $3 | $3 |
| EBITDA | $555 | -$4 | $5 | -$132 |
| % Margin | – | -11.5% | 13.5% | -129.3% |